Intellipharmaceutics International Inc.
IPCIQ
$0.00
$0.000.00%
OTC PK
| 08/31/2023 | 05/31/2023 | 02/28/2023 | 11/30/2022 | 08/31/2022 | |
|---|---|---|---|---|---|
| Revenue | 904.90K | 855.30K | 375.10K | 115.20K | 85.50K |
| Total Other Revenue | -- | -- | -- | 17.00K | 17.00K |
| Total Revenue | 904.90K | 855.30K | 375.10K | 132.20K | 102.50K |
| Cost of Revenue | 873.70K | -- | -- | -- | -- |
| Gross Profit | 31.20K | 855.30K | 375.10K | 132.20K | 102.50K |
| SG&A Expenses | 774.80K | 289.00K | 439.00K | 561.10K | 576.00K |
| Depreciation & Amortization | 173.40K | 184.30K | 195.30K | 206.10K | 219.90K |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 3.48M | 2.01M | 2.75M | 2.98M | 3.93M |
| Operating Income | -2.58M | -1.16M | -2.38M | -2.85M | -3.82M |
| Income Before Tax | -3.17M | -1.58M | -2.36M | -2.89M | -4.09M |
| Income Tax Expenses | 5.30K | 5.30K | 5.30K | 5.30K | -114.20K |
| Earnings from Continuing Operations | -3.17 | -1.58 | -2.37 | -2.89 | -3.97 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -3.17M | -1.58M | -2.37M | -2.89M | -3.97M |
| EBIT | -2.58M | -1.16M | -2.38M | -2.85M | -3.82M |
| EBITDA | -2.39M | -960.30K | -2.17M | -2.63M | -3.60M |
| EPS Basic | -0.09 | -0.04 | -0.06 | -0.08 | -0.12 |
| Normalized Basic EPS | -0.05 | -0.02 | -0.04 | -0.05 | -0.08 |
| EPS Diluted | -0.09 | -0.04 | -0.07 | -0.09 | -0.13 |
| Normalized Diluted EPS | -0.05 | -0.02 | -0.04 | -0.05 | -0.08 |
| Average Basic Shares Outstanding | 147.01M | 147.01M | 147.01M | 147.01M | 132.36M |
| Average Diluted Shares Outstanding | 147.01M | 147.01M | 147.01M | 147.01M | 132.36M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |